What is Chardan Capital's Forecast for RCKT FY2025 Earnings?

Key Points

• Chardan Capital has revised its FY2025 earnings forecast for Rocket Pharmaceuticals to ($2.01) per share, up from a previous estimate of ($2.04), and maintains a "Buy" rating with a price target of $11.00.
• Recent earnings showed Rocket Pharmaceuticals missed analyst expectations for the quarter, reporting ($0.59) EPS compared to a consensus of ($0.57).
• Institutional investors own 98.39% of Rocket Pharmaceuticals' stock, with several recently increasing their stakes significantly.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Chardan Capital upped their FY2025 earnings per share (EPS) estimates for shares of Rocket Pharmaceuticals in a research note issued on Monday, August 11th. Chardan Capital analyst Y. Livshits now anticipates that the biotechnology company will earn ($2.01) per share for the year, up from their prior estimate of ($2.04). Chardan Capital has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Chardan Capital also issued estimates for Rocket Pharmaceuticals' FY2026 earnings at ($1.19) EPS.

Other research analysts also recently issued research reports about the company. TD Cowen restated a "hold" rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, May 27th. Leerink Partnrs downgraded Rocket Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 27th. Cantor Fitzgerald cut their target price on Rocket Pharmaceuticals from $10.00 to $8.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Finally, Scotiabank lowered their price target on Rocket Pharmaceuticals from $51.00 to $19.00 and set a "sector outperform" rating on the stock in a report on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Rocket Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $16.33.

Rocket Pharmaceuticals Stock Down 1.5%

RCKT stock opened at $3.05 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.19 and a current ratio of 6.39. The company has a market capitalization of $328.56 million, a price-to-earnings ratio of -1.20 and a beta of 0.65. Rocket Pharmaceuticals has a fifty-two week low of $2.19 and a fifty-two week high of $22.01. The stock has a fifty day moving average of $2.95 and a 200-day moving average of $6.01.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.02). During the same quarter in the previous year, the company posted ($0.74) earnings per share.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of large investors have recently made changes to their positions in RCKT. Covestor Ltd grew its position in shares of Rocket Pharmaceuticals by 33,166.7% in the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock worth $25,000 after buying an additional 1,990 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter worth approximately $25,000. Farther Finance Advisors LLC grew its position in shares of Rocket Pharmaceuticals by 7,818.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 13,540 shares of the biotechnology company's stock worth $33,000 after buying an additional 13,369 shares during the last quarter. Corton Capital Inc. bought a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Rocket Pharmaceuticals in the 2nd quarter worth approximately $43,000. 98.39% of the stock is currently owned by institutional investors.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.